Bio-Imaging Rivals Lay Patent Claims To Rest
Under the settlement announced Tuesday, Caliber acquired the right to sublicense AntiCancer's fluorescent protein optical imaging patents to third parties. In exchange, AntiCancer may sublicense Caliper's patents regarding similar technology to a specified annual number of third parties.
The companies will also receive royalty-free licenses from each other for internal and contract research operations.
"This settlement and the resulting...
To view the full article, register now.